Skip to content

Tagar,Raktamokshan and Basti in the Management of Essential Hypertension.

Open Clinical Trial of Tagar,Basti and Raktamokshan in the Management of Essential Hypertension.

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/12/048447
Enrollment
53
Registered
2022-12-23
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: I10- Essential (primary) hypertension

Interventions

None listed

Sponsors

Dr Rashmi Jaiswal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients having high normal Blood pressure, Stage I hypertension, Stage II hypertension, isolated systolic and isolated diastolic hypertension. 2.Patients having history of hypertension less than 10 years 3.Patients who are willing to participate in trial and ready to give written informed consent. 4.Patients in between 18 to 70 years of age. 5.Patients having serum. creatinine level less than 1.4 mg/dl. 6.Patients who have not participated in any research project in last 6 months

Exclusion criteria

Exclusion criteria: 1.Patients who are not willing to participates in study and not ready to give written informed consent. 2.Patients having age below 18 years and above 70 years. 3.Patients having history of hypertension more than 10 years. 4.Patients having stage III and above hypertension will be excluded. 5.Patients having hypertension other than essential hypertension. 6.Patients with uncontrolled diabetes mellitus (Random Blood glucose level >200 mg/dl) 7.Pregnant women and lactating mothers. 8.Patients with serum. creatinine value more than 1.4 mg/dl. 9.Patients having Hb less than 9 gm%. 10Patient suffering from any other serious systemic illness. 11.Any other patients that physician feel should not include at that point of recruitment considering clinical scenario.

Design outcomes

Primary

MeasureTime frame
Reduction in Blood pressureTimepoint: 90 days

Secondary

MeasureTime frame
1- Estimated Risk of Developing CHD in 10 Years. (Day zero and Day 90) 2- Estimated Risk of Developing Hypertension in the next 4 Years. (Day zero and Day 90 Timepoint: 90 days

Countries

India

Contacts

Public ContactRashmi Ganesh Jaiswal

Government Ayurved College Nagpur

amitnakanekar@gmail.com9850233016

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026